Breast Cancer
Conditions
Brief summary
This is a randomized, parallel-controlled, open-label, multicenter clinical study to assess the efficacy and safety of D-0502 in the treatment of subjects with ER-positive, HER2-negative locally advanced or metastatic breast cancer with fulvestrant injection as a control drug.
Interventions
DRUGD-0502
* Dosage form: Tablet * Administration route: Oral, once a day
DRUGFulvestrant
* Dosage form: Injection * Administration route: Intramuscular injection, once a month, and another dose administered two weeks after the first dose
Sponsors
InventisBio Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Subjects pathologically confirmed with ER-positive, HER2-negative breast cancer; * Subjects with locally advanced (unresectable) or metastatic breast cancer who have disease recurrence during or after adjuvant endocrine therapy, or whose disease has progressed after 1-2 lines of systemic endocrine therapy; * Presence of at least 1 measurable lesion that can be measured by CT or MRI based on RECIST V1.1 criteria; in the absence of measurable lesions, subjects with evaluable bone lesions \[osteolytic or mixed (osteolytic + osteogenic) bone lesions\] are also acceptable. Lesions that have been previously treated with radiotherapy or other local therapy can be regarded as measurable lesions only if there is disease progression as confirmed by imaging examination; * Expected survival time ≥ 12 weeks;
Exclusion criteria
* Subjects with unstable or symptomatic or progressive central nervous system (CNS) metastases. Subjects with a history of brain metastases who are clinically stable and have no CNS disease progression confirmed by brain MRI or CT (if MRI is not appropriate) can be enrolled (MRI or CT examination must be conducted at least 4 weeks after the last brain radiotherapy); * Subjects with locally advanced or metastatic breast cancer who have previously received more than 2 prior systemic chemotherapy; * Subjects are unsuitable for endocrine therapy judged by the investigator, including uncontrolled pleural effusion, ascites or pericardial effusion; * Subjects with concomitant medical conditions that the investigator believes may increase the risk of toxicity, such as serious cardiovascular, respiratory or neurological diseases; * Prior treatment with a selective estrogen receptor degrader (SERD)/selective estrogen receptor covalent antagonist (SERCA), such as fulvestrant, GDC-9545, AZD9833, SAR-439859, Zn -c5, LX-039, HS234, etc.; * Pregnant or lactating females;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS) assessed by Independent Review Committee (IRC) | From enrollment to the end of treatment, up to 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival (PFS) -assessed by investigators | From enrollment to the end of treatment, up to 2 years |
| Objective response rate (ORR) -assessed by IRC and investigators | From enrollment to the end of treatment, up to 2 years |
| Clinical benefit rate (CBR) -assessed by IRC and investigators | From enrollment to the end of treatment, up to 2 years |
| Disease control rate (DCR)-assessed by IRC and investigators | From enrollment to the end of treatment, up to 2 years |
| Clearance (Cl) of D-0502 | on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 28 days) |
| Overall Survival (OS) | From end of treatment to end of study, about 2 years |
| Number of participants with adverse events/serious adverse events and abnormal laboratory test results | From enrollment to 30 days after last dose |
| Volume of distribution (Vd) of D-0502 | on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1 and Cycle 3 Day 1 (each cycle is 28 days) |
Countries
China
Contacts
PRINCIPAL_INVESTIGATORQingyuan Zhang, MD
Harbin
CONTACTYuting Li
PRINCIPAL_INVESTIGATORBinghe Xu, MD
Cancer Hospital
Outcome results
None listed